摘要
结外自然杀伤/T细胞淋巴瘤(ENKTCL)是非霍奇金淋巴瘤(NHL)的一种少见亚型。近年,ENKTCL发病率逐年上升,其具有侵袭性强、临床进展快、患者预后差等特点,目前尚缺乏统一的标准治疗方案。由于ENKTCL对放疗敏感,早期以放疗和综合治疗为主,晚期以左旋门冬酰胺酶(L-Asp)为基础的全身化疗可延长患者生存期,造血干细胞移植(HSCT)及嵌合抗原受体T细胞(CAR-T)免疫疗法为ENKTCL患者提供了新的治疗选择。笔者拟就ENKTCL的联合化疗、综合治疗、放疗、HSCT等研究新进展进行阐述,以期为ENKTCL的临床治疗提供参考。
Extranodal natural killer/T-cell lymphoma(ENKTCL)is a rare subtype of non-Hodgkin lymphoma(NHL).In recent years,prevalence rate of ENKTCL is increasing year by year,and it has characteristics of high invasiveness,speedy development and poor prognosis.At present,there is still lack of a unified standard treatment for ENKTCL.Because ENKTCL is sensitive to radiotherapy,radiotherapy and comprehensive treatment are chosen in the early stage while systemic chemotherapy based on L-asparaginase(L-Asp)in the late stage,which can prolong the survival time of patients.Hematopoietic stem cell transplantation(HSCT)and chimeric antigen receptor T cell(CAR-T)immunotherapy provide new therapeutic options for patients with ENKTCL.This article intends to describe progress of combined chemotherapy,comprehensive therapy,radiotherapy,HSCT and so on for patients with ENKTCL,in order to provide reference to clinical treatment.
作者
聂琳琳
朱锋
Nie Linlin;Zhu Feng(First Clinical Medical College of Xuzhou Medical University,Xuzhou 221000,Jiangsu Province,China;Department of Hematology,Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,Jiangsu Province,China)
出处
《国际输血及血液学杂志》
CAS
2022年第3期198-204,共7页
International Journal of Blood Transfusion and Hematology
基金
国家自然科学基金(82170187)
江苏省"六个一工程"拔尖人才科研项目(LGY2018084)。
关键词
淋巴瘤
结外NK-T细胞
淋巴瘤
非霍奇金
放射疗法
综合疗法
造血干细胞移植
免疫疗法
Lymphoma,extranodal NK-T-cell
Lymphoma,non-Hodgkin
Radiotherapy
Combined modality therapy
Hematopoietic stem cell transplantation
Immunotherapy
